Home | AREXVY
WEBAREXVY is a vaccine that helps to protect adults 60 years of age and older from lower lung disease caused by respiratory syncytial virus (RSV). CANADA'S 1ST RSV VACCINE MESSAGE FROM THE GREAT ONE
AREXVY | GSK Canada
WEBGSK plc. Registered in England and Wales No. 3888792. GlaxoSmithKline Inc. 100 Milverton Drive, Suite 800, Mississauga, ON L5R 4H1. > GSK Modern Slavery Act Statement 2023 (PDF - 154.2KB) GSK websites. GSK Global website. Market website selector. Global Behind the science magazine.
GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for ...
WEBAug 4, 2023 · GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults approved in Canada. Canadians aged 60 years and older can now better protect themselves against RSV disease. Approval of Arexvy was based on a comprehensive Phase III clinical trial program that showed high vaccine efficacy of …
RSV Vaccine | AREXVY (Respiratory Syncytial Virus Vaccine, …
WEBThe First FDA-Approved RSV Vaccine for People 60 Years and Older. AREXVY protects against lung and lower airway infection caused by respiratory syncytial virus (RSV).
About AREXVY | AREXVY (Respiratory Syncytial Virus Vaccine, …
WEBWhat Is AREXVY? AREXVY is an FDA-approved vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in people 60 years of age and older. Important Safety Information. You should not receive AREXVY if you are allergic to any of its ingredients
GSK's RSV vaccine, Arexvy, accepted for review by Health Canada …
WEBFeb 26, 2024 · MISSISSAUGA, ON - GSK (GlaxoSmithKline Inc.) has submitted a Supplementary New Drug Submission (SNDS) to Health Canada to expand the use of Arexvy, GSK’s respiratory syncytial virus (RSV) vaccine (recombinant, AS01 E adjuvanted), to include adults aged 50-59 at increased risk for RSV disease.
RSV vaccine in Canada: Ontario offers free Arexvy to eligible ... - CP24
WEBDec 12, 2023 · This year, eligible Ontario residents can receive Arexvy, a respiratory syncytial virus (RSV) vaccine authorized by Health Canada in August, for free. To many, RSV presents like a common cold and...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · AREXVY is the first approved RSV vaccine for older adults, expanding GSK’s industry-leading vaccine portfolio, which protects millions of people from infectious diseases each year. Our focus now is to ensure eligible older adults in the US can access the vaccine as quickly as possible and to progress regulatory review in other countries.”
GSK’s Arexvy, the First Respiratory Syncytial Virus (RSV) Vaccine …
WEBAug 4, 2023 · MISSISSAUGA, ON — Arexvy (respiratory syncytial virus vaccine – recombinant, AS01 E adjuvanted) has been approved in Canada for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. 1 The approval of Arexvy …
ABOUT RSV - AREXVY
WEBAREXVY is a vaccine that helps to protect adults 60 years of age and older from lower lung disease caused by respiratory syncytial virus (RSV). 100% protection cannot be guaranteed. AREXVY is not indicated for the treatment of RSV and does not prevent or reduce the risk of complications.